Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo OTC Growth Rides Innovation Path Wider Than Switches

Executive Summary

When Perrigo executives confirmed their faith during an earnings briefing in the firm's OTC private label as its primary revenue driver, some analysts wanted more as assurance that the business will continue stabilizing the firm.

Advertisement

Related Content

Perrigo Predicts Upturn On OTC Private Label Breadth, Depth And Bandwidth
Perrigo Predicts Upturn On OTC Private Label Breadth, Depth And Bandwidth
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
Perrigo Trims Workforce, Ships Tysabri License, Stays European Course
Light Still On For Switches After Pfizer Pulls Plug On OTC Lipitor

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel